“Bivalent” Vaccines Submitted for FDA Approval

Moderna and Pfizer incorporate subvariants into original formula.

The Food and Drug Administration has received requests for authorization of newly-developed COVID-19 vaccines from Moderna and Pfizer. The “bivalent” vaccine adds information from the BA.4 and BA.5 omicron subvariants to their original COVID-19 formula, creating a more complete vaccine for the current coronavirus outbreaks. FDA officials anticipate approvals of the new vaccines by Labor Day.

Centers for Disease Control and Prevention officials have stated that there are enough booster doses to ensure a “robust and complete national vaccination campaign through the fall and early winter.” Regarding the distribution and administration of new vaccines, they said, “There will be a sufficient but finite supply of bivalent COVID-19 vaccines, which should be directed to providers with expected demand among eligible patients.” 

As the Lord Leads, Pray with Us…

  • For FDA personnel as they review and evaluate the new bivalent vaccines.
  • For CDC officials as they monitor current data regarding the coronavirus and its variants.

Sources: The Hill, CNBC


Back to top